Live Breaking News & Updates on Innogene Kalbiotech

Stay updated with breaking news from Innogene kalbiotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

The Ngs Based Diagnostics Market To Grow Through Partnerships Amongst Market Participants – KSU


The Ngs Based Diagnostics Market To Grow Through Partnerships Amongst Market Participants
Ngs Based Diagnostics Market
5
The healthcare vertical is being driven at the consumers’ pace like never before. In other words, the requirements and goals on their part are driving innovation in every arm of the healthcare vertical. On-demand interactions between clinicians and patients all over the world are being asked for. As such, the healthcare vertical is bound to witness higher strides in the next 10 years. The Ngs Based Diagnostics Market is all set to incorporate the ongoing as well as future trend.
Next generation sequencing (NGS) based diagnostics are the medical devices used for diagnosis of various conditions using advanced generation sequencing platforms. They are unique from their earlier versions of first-generation dideoxy ‘Sanger’ sequencing and can perform parallel sequencing of several genomes simultaneously using a single instrument in less than t ....

New York , United States , Pacific Biosciences , Innogene Kalbiotech , Academics Research Institutions , Admera Health , Persistence Market Research , Phalanx Biotech Group , Janssen Global Services , Paradigm Diagnostics Inc , Illumina Inc , Oxford Gene Technology , Aitbiotech Pte Ltd , F Hoffmann La Roche Ltd , Ngs Based Diagnostics Market , Sample Copy , Genome Project , Latin America , Western Europe , Eastern Europe , Middle East , North America , Thermo Fisher Scientific , Pte Ltd , Market Research , New York City ,

PT Kalbe Farma Tbk (via Public) / General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics


General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics
General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics
Capital to fuel Company s strategic growth into a leading biologics platform in the Southeast Asia region
Jakarta, Indonesia - January 27, 2021 - Kalbe Genexine Biologics ( KGBio or the Company ), a leading integrate biologics holding company focused on the in-licensing, clinical development, and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio s ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts. ....

New York , United States , Hong Kong , Mexico City , Distrito Federal , City Of , United Kingdom , Noord Holland , Palo Alto , South Korea , Jakarta Raya , Medika Kalbio , Innogene Kalbiotech , Ashish Saboo , Irawaty Setiady , Kalbe Genexine Biologics Kgbio , Sandeep Naik , Kalbe Farma , Genexine Inc , Kalbe Group , Genexine Biologics , General Atlantic , Southeast Asia , President Commissioner , Managing Director , Sung Young Chul ,